The dawn of 2026 marks a transformative period for precision oncology as global health systems transition toward mandatory genomic profiling for early-stage malignancies. Under the latest WHO-aligned diagnostic frameworks, clinicians are no longer viewing biomarkers as optional data points but as the foundational architecture for therapeutic selection. This systemic pivot is currently most...
Turkish 
English
Arabic
French
Spanish
Portuguese
Deutsch
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt